Who’s next?_老虎社区_美港股上老虎

Yandaoxiang
2021-08-20

Who’s next?

Johnson & Johnson CEO stepping down in January<blockquote>强生公司首席执行官一月辞职</blockquote>

Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t

Johnson & Johnson CEO stepping down in January<blockquote>强生公司首席执行官一月辞职</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":836916325,"tweetId":"836916325","gmtCreate":1629446673367,"gmtModify":1631890225533,"author":{"id":3572095880096095,"idStr":"3572095880096095","authorId":3572095880096095,"authorIdStr":"3572095880096095","name":"Yandaoxiang","avatar":"https://static.tigerbbs.com/6330cd1176a93a8c564f8047fd53d835","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Who’s next?</p></body></html>","htmlText":"<html><head></head><body><p>Who’s next?</p></body></html>","text":"Who’s next?","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/836916325","repostId":1133561437,"repostType":4,"repost":{"id":"1133561437","kind":"news","pubTimestamp":1629445627,"share":"https://www.laohu8.com/m/news/1133561437?lang=zh_CN&edition=full","pubTime":"2021-08-20 15:47","market":"us","language":"en","title":"Johnson & Johnson CEO stepping down in January<blockquote>强生公司首席执行官一月辞职</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133561437","media":"FOX Business","summary":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will t","content":"<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p><p><blockquote><i>亚历克斯·戈尔斯基(Alex Gorsky)在担任强生公司首席执行官近十年后将卸任，华金·杜阿托(Joaquin Duato)将接任该职位。</i></blockquote></p><p> <a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p><p><blockquote><a href=\"https://laohu8.com/S/JNJ\">强生公司</a>该公司周四宣布，首席执行官亚历克斯·戈尔斯基将于一月份辞职。</blockquote></p><p> Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p><p><blockquote>强生公司执行委员会副主席华金·杜阿托(Joaquin Duato)将被任命为公司下一任首席执行官和董事会成员，自2022年1月3日起生效。</blockquote></p><p> Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p><p><blockquote>Duato在强生公司工作了30多年，在其业务部门担任过各种职务。他还是联合国儿童基金会美国分会、清华大学药学院和赫斯公司的董事会成员。</blockquote></p><p> <table>  <thead>   <tr>    <th>Ticker</th>    <th>Security</th>    <th>Last</th>    <th>Change</th>    <th>Change %</th>   </tr>  </thead>  <tbody>   <tr>    <td>JNJ</td>    <td>JOHNSON &amp; JOHNSON</td>    <td>178.57</td>    <td>+1.38</td>    <td>+0.78%</td>   </tr>   <tr></tr>  </tbody> </table> Duato said he was \"honored\" by the appointment.</p><p><blockquote><table><thead><tr><th>股票代码</th><th>安全</th><th>最后</th><th>变化</th><th>变化%</th></tr></thead><tbody><tr><td>JNJ</td><td>强生公司</td><td>178.57</td><td>+1.38</td><td>+0.78%</td></tr><tr></tr></tbody></table>杜阿托说，他对这一任命感到“荣幸”。</blockquote></p><p> \"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p><p><blockquote>他说：“随着世界继续面临重大健康挑战，包括持续的大流行，我对强生公司有机会在有意义地改善全球人类健康轨迹方面发挥关键作用感到鼓舞。”</blockquote></p><p> Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p><p><blockquote>戈尔斯基和杜阿托已经密切合作了25年，最近一次是在强生公司的COVID-19应对措施上。</blockquote></p><p> \"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p><p><blockquote>“除了推动我们的制药和消费者健康业务的加速增长和盈利能力之外，华金在最近担任执行委员会副主席期间，还帮助指导了我们的企业战略规划流程，涵盖公司的所有三个业务部门，并负责在过去一年中引领整个企业的重大技术转型，”戈尔斯基说。</blockquote></p><p> Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p><p><blockquote>戈尔斯基于2012年担任强生公司首席执行官近十年。在他领导公司期间，强生公司在研发方面进行了大量投资——2020年达到120亿美元——以及数百项收购和合作伙伴关系，包括2017年收购该公司有史以来最大的收购Actelion。</blockquote></p><p> Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p><p><blockquote>这些投资随着各业务部门的增长而获得回报。该公司表示，Gorsky对肿瘤学的关注帮助该领域的销售额从2011年的约20亿美元增长到去年的超过120亿美元。</blockquote></p><p> Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p><p><blockquote>戈尔斯基还带领公司度过了滑石粉法律问题等困难。该公司仍面临数千起指控产品致癌的诉讼。</blockquote></p><p> He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p><p><blockquote>他还监督了强生公司单针COVID-19疫苗的开发，以及治疗埃博拉和艾滋病毒等疾病的突破。</blockquote></p><p> Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p><p><blockquote>戈尔斯基将继续担任公司执行董事长。他表示，“出于家庭健康原因”，他希望更多地关注家人，但认为在“强劲表现”的情况下，现在是更换领导层的好时机。</blockquote></p><p> \"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p><p><blockquote>“作为董事长兼首席执行官领导这家公司近十年是一种荣誉和特权，我很高兴担任执行主席，帮助监督强生公司在改善世界各地人民和社区健康方面不断取得的进展，”他说。</blockquote></p><p> The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p><p><blockquote>这家总部位于新泽西州新不伦瑞克的公司在最新的季度收益报告中宣布销售额为233亿美元。该公司净利润为63亿美元，调整后每股收益为2.48美元。</blockquote></p><p> <ul></ul></p><p><blockquote><ul></ul></blockquote></p><p></p>","source":"lsy1602566126337","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Johnson & Johnson CEO stepping down in January<blockquote>强生公司首席执行官一月辞职</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJohnson & Johnson CEO stepping down in January<blockquote>强生公司首席执行官一月辞职</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">FOX Business</strong><span class=\"h-time small\">2021-08-20 15:47</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i>Alex Gorsky will step down after nearly a decade as Johnson &amp; Johnson's CEO and Joaquin Duato will take over the role.</i></p><p><blockquote><i>亚历克斯·戈尔斯基(Alex Gorsky)在担任强生公司首席执行官近十年后将卸任，华金·杜阿托(Joaquin Duato)将接任该职位。</i></blockquote></p><p> <a href=\"https://laohu8.com/S/JNJ\">Johnson &amp; Johnson</a> CEO&nbsp;Alex Gorskywill step down in January, the company announced Thursday.</p><p><blockquote><a href=\"https://laohu8.com/S/JNJ\">强生公司</a>该公司周四宣布，首席执行官亚历克斯·戈尔斯基将于一月份辞职。</blockquote></p><p> Joaquin Duato, the vice chairman of Johnson &amp; Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.</p><p><blockquote>强生公司执行委员会副主席华金·杜阿托(Joaquin Duato)将被任命为公司下一任首席执行官和董事会成员，自2022年1月3日起生效。</blockquote></p><p> Duato has spent more than 30 years with Johnson &amp; Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.</p><p><blockquote>Duato在强生公司工作了30多年，在其业务部门担任过各种职务。他还是联合国儿童基金会美国分会、清华大学药学院和赫斯公司的董事会成员。</blockquote></p><p> <table>  <thead>   <tr>    <th>Ticker</th>    <th>Security</th>    <th>Last</th>    <th>Change</th>    <th>Change %</th>   </tr>  </thead>  <tbody>   <tr>    <td>JNJ</td>    <td>JOHNSON &amp; JOHNSON</td>    <td>178.57</td>    <td>+1.38</td>    <td>+0.78%</td>   </tr>   <tr></tr>  </tbody> </table> Duato said he was \"honored\" by the appointment.</p><p><blockquote><table><thead><tr><th>股票代码</th><th>安全</th><th>最后</th><th>变化</th><th>变化%</th></tr></thead><tbody><tr><td>JNJ</td><td>强生公司</td><td>178.57</td><td>+1.38</td><td>+0.78%</td></tr><tr></tr></tbody></table>杜阿托说，他对这一任命感到“荣幸”。</blockquote></p><p> \"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson &amp; Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.</p><p><blockquote>他说：“随着世界继续面临重大健康挑战，包括持续的大流行，我对强生公司有机会在有意义地改善全球人类健康轨迹方面发挥关键作用感到鼓舞。”</blockquote></p><p> Gorsky and Duato have worked closely together for 25 years, most recently on Johnson &amp; Johnson's COVID-19 response.</p><p><blockquote>戈尔斯基和杜阿托已经密切合作了25年，最近一次是在强生公司的COVID-19应对措施上。</blockquote></p><p> \"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.</p><p><blockquote>“除了推动我们的制药和消费者健康业务的加速增长和盈利能力之外，华金在最近担任执行委员会副主席期间，还帮助指导了我们的企业战略规划流程，涵盖公司的所有三个业务部门，并负责在过去一年中引领整个企业的重大技术转型，”戈尔斯基说。</blockquote></p><p> Gorsky has served as Johnson &amp; Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson &amp; Johnson make significant investments in research and development –&nbsp;hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.</p><p><blockquote>戈尔斯基于2012年担任强生公司首席执行官近十年。在他领导公司期间，强生公司在研发方面进行了大量投资——2020年达到120亿美元——以及数百项收购和合作伙伴关系，包括2017年收购该公司有史以来最大的收购Actelion。</blockquote></p><p> Those investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.</p><p><blockquote>这些投资随着各业务部门的增长而获得回报。该公司表示，Gorsky对肿瘤学的关注帮助该领域的销售额从2011年的约20亿美元增长到去年的超过120亿美元。</blockquote></p><p> Gorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.</p><p><blockquote>戈尔斯基还带领公司度过了滑石粉法律问题等困难。该公司仍面临数千起指控产品致癌的诉讼。</blockquote></p><p> He also oversaw the development of Johnson &amp; Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.</p><p><blockquote>他还监督了强生公司单针COVID-19疫苗的开发，以及治疗埃博拉和艾滋病毒等疾病的突破。</blockquote></p><p> Gorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"</p><p><blockquote>戈尔斯基将继续担任公司执行董事长。他表示，“出于家庭健康原因”，他希望更多地关注家人，但认为在“强劲表现”的情况下，现在是更换领导层的好时机。</blockquote></p><p> \"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson &amp; Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.</p><p><blockquote>“作为董事长兼首席执行官领导这家公司近十年是一种荣誉和特权，我很高兴担任执行主席，帮助监督强生公司在改善世界各地人民和社区健康方面不断取得的进展，”他说。</blockquote></p><p> The New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.</p><p><blockquote>这家总部位于新泽西州新不伦瑞克的公司在最新的季度收益报告中宣布销售额为233亿美元。该公司净利润为63亿美元，调整后每股收益为2.48美元。</blockquote></p><p> <ul></ul></p><p><blockquote><ul></ul></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down\">FOX Business</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.foxbusiness.com/markets/johnson-johnson-ceo-stepping-down","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133561437","content_text":"Alex Gorsky will step down after nearly a decade as Johnson & Johnson's CEO and Joaquin Duato will take over the role.\nJohnson & Johnson CEO Alex Gorskywill step down in January, the company announced Thursday.\nJoaquin Duato, the vice chairman of Johnson & Johnson’s executive committee, will be appointed the company’s next CEO and a member of its board of directors effective Jan. 3, 2022.\nDuato has spent more than 30 years with Johnson & Johnson, serving in a variety of roles across its business segments. He also sits on the boards of UNICEF USA, Tsinghua University School of Pharmaceutical Sciences, and the Hess Corporation.\n\n\n\nTicker\nSecurity\nLast\nChange\nChange %\n\n\n\n\nJNJ\nJOHNSON & JOHNSON\n178.57\n+1.38\n+0.78%\n\n\n\n\nDuato said he was \"honored\" by the appointment.\n\"As the world continues to face significant health challenges, including the ongoing pandemic, I am inspired by Johnson & Johnson’s opportunity to play a key role in meaningfully improving the global trajectory of human health,\" he said.\nGorsky and Duato have worked closely together for 25 years, most recently on Johnson & Johnson's COVID-19 response.\n\"In addition to driving accelerated growth and profitability in our pharmaceutical and consumer health businesses, in his most recent role of vice chairman of the executive committee, Joaquin helped guide our enterprise strategic planning process, encompassing all three of the company’s business segments, and was responsible for spearheading a significant technology transformation across the enterprise over the past year,\" Gorsky said.\nGorsky has served as Johnson & Johnson’s CEO for close to a decade, taking the role in 2012. His time leading the company saw Johnson & Johnson make significant investments in research and development – hitting $12 billion in 2020 – as well as hundreds of acquisitions and partnerships, including the purchase of Actelion, the company's largest-ever acquisition, in 2017.\nThose investments paid off with growth across business segments. Gorsky's focus on oncology helped grow sales in the area from about $2 billion in 2011 to more than $12 billion last year, the company said.\nGorsky also led the company through difficulties like its legal problems over talcum powder. The company is still facing thousands of lawsuits over allegations the products caused cancer.\nHe also oversaw the development of Johnson & Johnson's single-shot COVID-19 vaccine, as well as breakthroughs for treating diseases like Ebola and HIV.\nGorsky will remain with the company as executive chairman. He said he wants to focus more on his family \"due to family health reasons,\" but believes this is a good time for a change in leadership amid \"strong performance.\"\n\"It has been an honor and privilege to lead this company as chairman and CEO for nearly a decade, and I am pleased to serve as executive chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,\" he said.\nThe New Brunswick, N.J.-based company announced $23.3 billion in sales in its latest quarterly earnings report. It netted $6.3 billion, an adjusted $2.48 per share.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2537,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}